The French vaccine developer is leaning on asset sales and aggressive cost discipline to steady its balance sheet while investors await a slate of pipeline catalysts. Valneva has signed a preliminary agreement to offload its Nantes facility to Nantes Métropole for €6.2 million, with the transaction expected to close in September.
The divestment forms part of a broader restructuring blueprint unveiled in mid-August. That program pairs the real estate disposal with substantial workforce reductions and a reprioritization of research activities, all aimed at curtailing the company’s cash burn.
Half-Year Results Expose Margin Pressure
The urgency behind these measures becomes apparent in the interim figures published on August 13. Valneva’s net loss ballooned to €63.3 million from €20.8 million in the corresponding period last year, driven by a compressed gross margin on lower sales and production volumes. One-off manufacturing costs added to the damage, including contract termination expenses tied to the chikungunya vaccine IXCHIQ and inventory write-downs.
Product revenue for the first half reached €64.0 million. Despite the deeper loss, the company’s cash position actually improved — liquid assets stood at €121.5 million as of June 30, up from €109.7 million at the close of 2025. That uplift partly reflects the early impact of the savings initiatives, alongside gross proceeds of €37 million from a reserved capital raise completed in the second quarter.
Management has reaffirmed its full-year outlook, targeting product sales between €135 million and €150 million and total revenue of €145 million to €160 million. The guidance implies a markedly stronger back half, given that the first six months contributed less than half of the lower-end product revenue figure.
Pipeline Data Points Loom
Beyond the balance-sheet repair work, Valneva is pointing to near-term clinical milestones. Third-quarter results are expected from a Phase 2 safety and immunogenicity study of the shigellosis candidate S4V2 in infants, as well as from a Phase 2b human challenge trial sponsored by LimmaTech Biologics AG.
Should investors sell immediately? Or is it worth buying Valneva?
Those readouts carry particular weight for shareholders because they would diversify the value drivers beyond the already-submitted regulatory application for the Lyme disease vaccine candidate developed with Pfizer.
Share Price Recovers From Summer Lows
The equity has shown signs of stabilization after a bruising stretch. Friday’s closing price of €2.98 sits roughly 46 percent above the 52-week trough of €2.03 touched on July 24, with the stock advancing 33 percent over the past month. The shares now trade about 21 percent above their 50-day moving average of €2.45.
Still, the recovery remains incomplete. The stock is down 20 percent year-to-date and stands 44 percent below its 52-week peak of €5.34 reached on October 1. A routine regulatory filing on September 4 detailing share and voting rights as of August 31 added no operational news but fulfilled ongoing disclosure obligations.
The coming weeks — bringing both the shigellosis data and the Nantes closing — should offer a clearer read on whether the restructuring momentum can translate into sustained financial stability. For now, the combination of reaffirmed guidance, a firmer cash buffer, and imminent clinical catalysts gives investors a tangible framework for judging the company’s trajectory through the remainder of the year.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from September 6 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.
Valneva: Buy or sell? Read more here...
